Industry news

• Industry news
• Musculoskeletal

Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain

Raritan, NJ - (August 30, 2010) - Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation. In addition, this study compared oxycodone controlled release (CR) to placebo as an active control. more

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
Category	Therapeutic target
Deals and Alliances Development Financial Results Financings Intellectual Property Regulatory	Cardiovascular Dermatology Endocrine and Metabolic Gastroenterology Genitourinary Hematology Immunology and Allergy Infection Musculoskeletal Neurology Obstetrics and Gynecology Oncology Ophthalmology Psychiatry Pulmonary
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Most Viewed

Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain